BL
MCID: BRK010
MIFTS: 69

Burkitt Lymphoma (BL)

Categories: Blood diseases, Cancer diseases, Genetic diseases, Rare diseases

Aliases & Classifications for Burkitt Lymphoma

MalaCards integrated aliases for Burkitt Lymphoma:

Name: Burkitt Lymphoma 58 12 54 60 76 38 30 13 56 6 45 15 39 41 74
Burkitt's Lymphoma 39 12 77 54 15
Bl 58 54 76
Small Non-Cleaved Cell Lymphoma, Burkitt's Type 12
Malignant Lymphoma, Burkitt's Type 12
Small Non-Cleaved Cell Lymphoma 60
Lymphoma, Small Noncleaved-Cell 74
Burkitt's Tumor or Lymphoma 12
Burkitt Lymphoma/leukaemia 12
Burkitt Lymphoma, Somatic 58
Burkitts Lymphoma 17
Burkitt's Tumor 12
Burkitt Tumor 76

Characteristics:

Orphanet epidemiological data:

60
burkitt lymphoma
Inheritance: Not applicable; Prevalence: 1-9/1000000 (Europe),1-5/10000 (Africa),1-9/1000000 (United States); Age of onset: All ages; Age of death: any age;

OMIM:

58
Inheritance:
somatic mutation
isolated cases

Miscellaneous:
accounts for 30-50% of lymphomas in children
accounts for 1-2% of lymphomas in adults
three distinct clinical forms - endemic (equatorial africa), sporadic, and immunodeficiency-associated (e.g., hiv infection)


HPO:

33
burkitt lymphoma:
Inheritance sporadic


Classifications:



External Ids:

Disease Ontology 12 DOID:8584
OMIM 58 113970
KEGG 38 H00008
ICD9CM 36 200.2
MeSH 45 D002051
NCIt 51 C2912 C7400
SNOMED-CT 69 22197008 77381001
ICD10 34 C83.7 C83.70
MESH via Orphanet 46 D002051 D008228
ICD10 via Orphanet 35 C83.7
UMLS via Orphanet 75 C0006413 C0079770
Orphanet 60 ORPHA543
MedGen 43 C0006413

Summaries for Burkitt Lymphoma

NIH Rare Diseases : 54 Burkitt lymphoma (BL) is a very fast-growing type of cancer. It is a form of B-cellnon-Hodgkin's lymphoma. There are 3 recognized forms of BL: Endemic (African) - the most common form, found mainly in central Africa, where it is associated with the Epstein Barr virus (EBV). It is most common in children. This form often manifests as enlargement of the jaw or facial bones. Sporadic - a rarer form, seen in all parts of the world, that often develops in the abdomen with bone marrow involvement. The kidneys, ovaries, breasts or other organs may also be involved. This form commonly affects children and young adults. Immunodeficiency-associated - occurs primarily in people with HIV infection, and less commonly in people with other immunodeficiency disorders or recipients of organ transplants. Signs and symptoms may differ depending on the form of BL and the organs or body systems involved. When it spreads, weakness and fatigue often develop. Lymphoma cells may build up in the lymph nodes and other organs, causing swelling. Central nervous system involvement is possible with all forms of BL, particularly when there is advanced-stage disease.The exact cause of BL is not known. EBV infection appears to play a role in virtually all cases of endemic (African) BL, and a minority of sporadic and immunodeficiency-associated BL. While acquired (not inherited) genetic changes involving the MYC gene and other genes are present within BL cancer cells, it is unclear what causes these genetic changes to occur. Without timely treatment, BL is rapidly fatal. Treatment involves intensive chemotherapy, which includes chemotherapy to the fluid surrounding the brain and spinal cord. The majority of people treated with aggressive therapy achieve long-term remission.

MalaCards based summary : Burkitt Lymphoma, also known as burkitt's lymphoma, is related to lymphoma and diffuse large b-cell lymphoma. An important gene associated with Burkitt Lymphoma is MYC (MYC Proto-Oncogene, BHLH Transcription Factor), and among its related pathways/superpathways are Viral carcinogenesis and Epstein-Barr virus infection. The drugs Abraxane and Abstral have been mentioned in the context of this disorder. Affiliated tissues include Blood and Blood, and related phenotypes are hyperuricemia and increased lactate dehydrogenase activity

Disease Ontology : 12 A mature B-cell neoplasm of B-cells found in the germinal center.

OMIM : 58 Burkitt lymphoma is a rare, aggressive B-cell lymphoma that accounts for 30 to 50% of lymphomas in children but only 1 to 2% of lymphomas in adults (Harris and Horning, 2006). It results from chromosomal translocations that involve the MYC gene (190080) and either the lambda or the kappa light chain immunoglobulin genes (147220, 147200). Burkitt lymphoma is causally related to the Epstein-Barr virus (EBV), although the pathogenetic mechanisms are not clear. (113970)

UniProtKB/Swiss-Prot : 76 Burkitt lymphoma: A form of undifferentiated malignant lymphoma commonly manifested as a large osteolytic lesion in the jaw or as an abdominal mass.

Wikipedia : 77 Burkitt lymphoma is a cancer of the lymphatic system, particularly B lymphocytes found in the germinal... more...

Related Diseases for Burkitt Lymphoma

Diseases related to Burkitt Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 338)
# Related Disease Score Top Affiliating Genes
1 lymphoma 32.7 BAX BCL6 CXCR5 MYC PVT1 SH2D1A
2 diffuse large b-cell lymphoma 31.5 BCL6 MIR127 MIR143 MIR145 MIR155 MYC
3 follicular lymphoma 31.0 AICDA BCL6 MIR155 MYC
4 lymphoma, hodgkin, classic 31.0 BCL6 MIR155 PVT1
5 b-cell lymphomas 30.7 AICDA BAX BCL6 MS4A1 MYC PVT1
6 lymphoma, non-hodgkin, familial 30.6 AICDA BAX BCL6 CXCR5 MS4A1 MYC
7 autoimmune lymphoproliferative syndrome, type v 30.6 BCL6 SH2D1A TCL1A
8 acquired immunodeficiency syndrome 30.5 BCL6 MYC NEAT1
9 plasmablastic lymphoma 30.5 BCL6 MS4A1 MYC
10 precursor t-cell acute lymphoblastic leukemia 30.5 BAX MYC TCL1A
11 leukemia, chronic lymphocytic 30.4 AICDA BAX BCL6 CXCR5 MS4A1 TCL1A
12 suppressor of tumorigenicity 3 30.3 BAX MYC
13 nasopharyngeal carcinoma 29.9 MIR34B MYC NEAT1 PVT1
14 leukemia, acute myeloid 29.3 MIR155 MIR34B MIRLET7C MYC
15 leukemia, chronic lymphocytic 2 29.3 MIR143 MIR145 MIR155 NEAT1 TP53COR1
16 breast cancer 28.8 BAX MIR127 MIR143 MIR145 MIR155 MYC
17 ovarian cancer 28.7 BAX MIR127 MIR143 MIR145 MIR155 MIR34B
18 hepatocellular carcinoma 28.5 BAX MIR127 MIR143 MIR145 MIR155 MIRLET7C
19 small non-cleaved cell lymphoma 12.7
20 bare lymphocyte syndrome, type ii 12.1
21 bare lymphocyte syndrome, type i 11.9
22 leukemia, acute lymphoblastic 3 11.3
23 childhood ovarian cancer 11.3
24 blind loop syndrome 11.3
25 hypothyroidism, thyroidal or athyroidal, with spiky hair and cleft palate 11.1
26 leukemia 10.7
27 primary cutaneous cd4+ small/medium-sized pleomorphic t-cell lymphoma 10.6 BCL6 CXCR5
28 high grade b-cell lymphoma with myc and/ or bcl2 and/or bcl6 rearrangement 10.6 BCL6 MYC
29 primary effusion lymphoma 10.6 BCL6 MYC TCL1A
30 leukocyte disease 10.6 BAX BCL6 MYC
31 lymphoma, mucosa-associated lymphoid type 10.6 BCL6 CXCL13 CXCR5
32 lymphatic system cancer 10.5 BCL6 MYC SH2D1A
33 neurosyphilis 10.5 CXCL13 CXCR5
34 mature b-cell neoplasm 10.5 BCL6 MYC PVT1 SH2D1A
35 primary mediastinal large b-cell lymphoma 10.5 BCL6 MYC
36 t-cell prolymphocytic leukemia 10.5 MS4A1 MYC TCL1A
37 hematologic cancer 10.5 BAX BCL6 MYC PVT1
38 diversion colitis 10.5 CXCL13 CXCR5
39 peripheral t-cell lymphoma 10.5 BCL6 CXCL13 MS4A1 TCL1A
40 polymyositis 10.5 MIR127 MIR155
41 schuurs-hoeijmakers syndrome 10.5 AICDA TCL1A
42 malaria 10.5
43 intraocular lymphoma 10.4 BCL6 CXCR5
44 pancreatic ductal adenocarcinoma 10.4 MIR143 MIR145 MIR155 PVT1
45 lymphocytic leukemia 10.4
46 ovarian serous carcinoma 10.4 MIR143 MIR145
47 b cell prolymphocytic leukemia 10.4 MS4A1 MYC
48 acrocallosal syndrome 10.3
49 intussusception 10.3
50 leukemia, acute lymphoblastic 10.3

Graphical network of the top 20 diseases related to Burkitt Lymphoma:



Diseases related to Burkitt Lymphoma

Symptoms & Phenotypes for Burkitt Lymphoma

Human phenotypes related to Burkitt Lymphoma:

60 33 (show all 16)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 hyperuricemia 60 33 frequent (33%) Frequent (79-30%) HP:0002149
2 increased lactate dehydrogenase activity 60 33 frequent (33%) Frequent (79-30%) HP:0025435
3 abnormality of bone marrow cell morphology 60 33 frequent (33%) Frequent (79-30%) HP:0005561
4 neoplasm of the oral cavity 60 33 frequent (33%) Frequent (79-30%) HP:0100649
5 nausea and vomiting 60 33 occasional (7.5%) Occasional (29-5%) HP:0002017
6 abdominal pain 60 33 occasional (7.5%) Occasional (29-5%) HP:0002027
7 abnormality of the ovary 60 33 occasional (7.5%) Occasional (29-5%) HP:0000137
8 intestinal obstruction 60 33 occasional (7.5%) Occasional (29-5%) HP:0005214
9 abnormality of the pancreas 60 33 occasional (7.5%) Occasional (29-5%) HP:0001732
10 gastrointestinal hemorrhage 60 33 occasional (7.5%) Occasional (29-5%) HP:0002239
11 abnormality of the spleen 60 33 occasional (7.5%) Occasional (29-5%) HP:0001743
12 decreased proportion of cd4-positive t cells 60 33 occasional (7.5%) Occasional (29-5%) HP:0005407
13 abnormality of the liver 60 33 occasional (7.5%) Occasional (29-5%) HP:0001392
14 abnormality of the lymph nodes 60 33 occasional (7.5%) Occasional (29-5%) HP:0002733
15 immunodeficiency 33 HP:0002721
16 burkitt lymphoma 33 HP:0030080

Symptoms via clinical synopsis from OMIM:

58
Neoplasia:
burkitt lymphoma (b-cell lymphoma)
jaw and kidney tumor (endemic form)
ileal, cecal, ovarian, and breast tumors, occasionally (endemic form)
abdominal tumors (immunodeficiency-associated form)
monomorphic cells, medium-sized, with round nuclei, multiple nucleoli, and moderate amount of cytoplasm
more
Laboratory Abnormalities:
elevated lactate dehydrogenase
elevated uric acid
chromosomal translocations involving c-myc ( , 8q24) and the immunoglobin lambda light chain ( , 22q11.2) locus
chromosomal translocations involving c-myc ( , 8q24) and the immunoglobin kappa light chain ( , 2p12) locus
chromosomal translocations involving c-myc ( , 8q24) and the immunoglobin heavy chain ( , 14q32) locus

Clinical features from OMIM:

113970

Drugs & Therapeutics for Burkitt Lymphoma

FDA approved drugs:

(show top 50) (show all 227)
# Drug Name Active Ingredient(s) 19 Company Approval Date
1
Abraxane 19 50 PACLITAXEL Celgene October 2012
2
Abstral 19 FENTANYL (citrate) ProStrakan January 2011
3
Actiq 19 FENTANYL (citrate) Anesta Corporation November 1998
4
Adcetris 19 50 BRENTUXIMAB VEDOTIN Seattle Genetics August 2011
5
Afinitor 19 50 EVEROLIMUS Novartis March 2009
6
Akynzeo 19 50 NETUPITANT AND PALONOSETRON (hydrochloride) Helsinn October 2014
7
Alimta 19 50 PEMETREXED (also Pemetrexed Disodium) Eli Lilly February 2004
8
Aloxi 19 50 PALONOSETRON (hydrochloride) MGI Pharma, Helsinn Healthcare August 2003
9
Anzemet 19 DOLASETRON MESYLATE Hoechst Marion Roussel February 1998
10
Aredia 19 50 PAMIDRONATE DISODIUM Chiron August 1996
11
Aromasin Tablets 19 50 EXEMESTANE Pharmacia & Upjohn October 21. 1999
12
Arranon 19 50 NELARABINE GlaxoSmithKline October 2005
13
Arzerra 19 50 OFATUMUMAB GlaxoSmithKline October 2009
14
Avastin 19 50 BEVACIZUMAB Genentech July 2009
15
Beleodaq 19 50 BELINOSTAT Spectrum Pharmaceuticals July 2014
16
Bexxar 19 50 TOSITUMOMAB; IODINE I 131 TOSITUMOMAB Corixa June 2003
17
Blincyto 19 50 BLINATUMOMAB Amgen December 2014
18
Bosulif 19 50 BOSUTINIB MONOHYDRATE Pfizer September 2012
19
Bromfenac 19 BROMFENAC SODIUM Duract, Wyeth-Ayerst Laboratories July 1997
20
Busulfex 19 50 BUSULFAN Orphan Medical February 1999
21
Campath 19 50 ALEMTUZUMAB Berlex Laboratories May 2001
22
Cervarix 19 50 Human Papillomavirus Bivalent (Types 16 and 18) Vaccine, Recombinant GlaxoSmithKline October 2009
23
Clolar 19 50 CLOFARABINE Genzyme December, 2004
24
Cometriq 19 50 CABOZANTINIB S-MALATE Exelixis November 2012
25
Cyramza 19 50 RAMUCIRUMAB Eli Lilly April 2014
26
Degarelix 19 50 degarelix Ferring Pharmaceuticals December of 2008
27
Doxil 19 50 DOXORUBICIN HYDROCHLORIDE Alza June 1999
28
Elitek 19 50 RASBURICASE sanofi-aventis October 2009
29
Ellence 19 50 EPIRUBICIN HYDROCHLORIDE Pharmacia & Upjohn September 1999
30
Elliotts B Solution 19 CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE Orphan Medical October 1996
31
Eloxatin 19 50 OXALIPLATIN Sanofi-aventis August 2002
32
Emend 19 50 APREPITANT FOSAPREPITANT DIMEGLUMINE Merck March 2003
33
Erbitux 19 50 CETUXIMAB Imclone, Bristol-Myers Squibb February 2004
34
Erivedge 19 50 VISMODEGIB Genentech January 2012
35
Erwinaze 19 50 asparaginase Erwinia chrysanthemi Eusa Pharma November of 2011
36
Ethyol 19 AMIFOSTINE Alza December 8, 1995
37
Eulexin 19 FLUTAMIDE Schering-Plough June 1996
38
Evista 19 50 RALOXIFENE HYDROCHLORIDE Eli Lilly September 2007
39
Farydak 19 50 PANOBINOSTAT LACTATE Novartis February 2015
40
Faslodex 19 50 FULVESTRANT AstraZeneca April 2002
41
Femara 19 50 LETROZOLE Novartis January 2001
42
Feridex I.V. 19 FERUMOXIDES Advanced Magnetics February 1996
43
Folotyn 19 50 PRALATREXATE Allos Therapeutics September 2009
44
Fusilev 19 LEVOLEUCOVORIN CALCIUM Spectrum Pharmaceuticals March of 2008
45
Gardasil 19 50 quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine Merck June 2006
46
Gazyva 19 50 OBINUTUZUMAB Genentech October of 2013
47
Gemzar 19 50 GEMCITABINE HYDROCHLORIDE Eli Lilly May 1996
48
Gilotrif 19 50 AFATINIB DIMALEATE Boehringer Ingelheim July 2013
49
Gleevec 19 50 IMATINIB MESYLATE Novartis May 2001
50
Gliadel Wafer 19 50 CARMUSTINE Rhone-Poulenc Rorer, Guilford Pharmaceuticals February 1997

Drugs for Burkitt Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 521)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Vincristine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 2068-78-2, 57-22-7 5978
2
Ifosfamide Approved Phase 4,Phase 3,Phase 2,Phase 1 3778-73-2 3690
3
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 53-03-2 5865
4
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 50-18-0, 6055-19-2 2907
5
Cytarabine Approved, Experimental, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 147-94-4, 65-46-3 6253
6
rituximab Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 174722-31-7 10201696
7
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 1177-87-3
8
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 50-02-2 5743
9
Tenofovir Approved, Experimental, Investigational Phase 4 147127-20-6 464205
10
Methotrexate Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 1959-05-2, 59-05-2 126941
11
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-24-8 5755
12
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 302-25-0
13
Methylprednisolone hemisuccinate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 2921-57-5
14
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 83-43-2 6741
15
Etoposide Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 33419-42-0 36462
16
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 23214-92-8 31703
17
Mitoxantrone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 65271-80-9 4212
18
Lenograstim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 135968-09-1
19
Vindesine Approved, Investigational Phase 4,Phase 3,Phase 2 53643-48-4, 59917-39-4 40839
20
leucovorin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 58-05-9 143 6006
21
inotuzumab ozogamicin Approved, Investigational Phase 4,Phase 1,Phase 2 635715-01-4
22
Mercaptopurine Approved Phase 4,Phase 3,Phase 2 50-44-2 667490
23
Teniposide Approved Phase 4,Phase 2,Phase 1 29767-20-2 34698
24
Thioguanine Approved Phase 4,Phase 3,Phase 2 154-42-7 2723601
25
Daunorubicin Approved Phase 4,Phase 3,Phase 2,Phase 1 20830-81-3 30323
26
Cetylpyridinium Approved Phase 4 7773-52-6
27
Thiotepa Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 52-24-4 5453
28
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 59-30-3 6037
29
Doxil Approved June 1999 Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 31703
30
Prednisolone hemisuccinate Experimental Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 2920-86-7
31
Isophosphamide mustard Phase 4,Phase 3,Phase 2,Phase 1 0
32 Antineoplastic Agents, Immunological Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
33 BB 1101 Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
34 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
35 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
36 Anti-HIV Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
37 Reverse Transcriptase Inhibitors Phase 4,Phase 2,Not Applicable
38 Anti-Retroviral Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
39 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
40 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
41 Antiviral Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
42 Antineoplastic Agents, Alkylating Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
43 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
44 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
45 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
46 Prednisolone acetate Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
47 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
48 Etoposide phosphate Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
49 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
50 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 768)
# Name Status NCT ID Phase Drugs
1 Intensification Therapy of Mature B-ALL, Burkitt and Burkitt Like and Other High Grade Non-Hodgkin's Lymphoma in Adults Unknown status NCT00797810 Phase 4 Rituximab
2 To Compare the Efficacy of a Prophylactic Use of Tenofovir by Duration for the Non-Hodgkin's Lymphoma Unknown status NCT02585947 Phase 4 Tenofovir
3 Trial for the Treatment of Newly Diagnosed Mature B-Cell Acute Lymphoblastic Leukemia (B-ALL), Burkitt's Non-Hodgkin's Lymphoma (NHL) and Other High-grade Lymphoma in Adults Completed NCT00199082 Phase 4 Adriamycin;Cyclophosphamide;Cytarabine;Dexamethasone/Prednisolone;VP16;Ifosfamide;Methotrexate;G-CSF;Rituximab;Vincristine/Vindesine
4 Identification of New Immune Factors Specific of Relapse in Childhood B Lineage Acute Lymphoblastic Leukemia Recruiting NCT02618109 Phase 4
5 A Study Of Two Inotuzumab Ozogamicin Doses in Relapsed/ Refractory Acute Lymphoblastic Leukemia Transplant Eligible Patients Recruiting NCT03677596 Phase 4 inotuzumab ozogamicin-dose level 2;Inotuzumab ozogamicin-dose level 1
6 German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (05/93) Completed NCT00199069 Phase 4 Asparaginase;Vincristine;Daunorubicin, Adriamycin;Cyclophosphamide;Ifosfamide;Cytarabine;Mitoxantrone;Methotrexate;6-Mercaptopurine;6-Thioguanine;VM26;Dexamethasone / Prednisolone
7 Cetylpyridium Chloride (CPC) Based Chewing Gum and Gingivitis Active, not recruiting NCT03219840 Phase 4 CPC;Placebo
8 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
9 LMBA02 Protocol for Patients With a Burkitt Lymphoma Unknown status NCT00180882 Phase 3 rituximab
10 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3 ketamine hydrochloride
11 Early Hospital Discharge or Standard Inpatient Care in Cancer Patients Receiving Antibiotics for Febrile Neutropenia Unknown status NCT00445497 Phase 3 amoxicillin-clavulanate potassium;ciprofloxacin
12 Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia Unknown status NCT00020865 Phase 3 cefepime hydrochloride;levofloxacin
13 Monoclonal Antibodies in Detecting Residual Disease in Patients Who Have Been Treated for Non-Hodgkin's Lymphoma Unknown status NCT00003338 Phase 2, Phase 3
14 Radiolabeled Monoclonal Antibody in the Detection and Staging of Patients With Non-Hodgkin's Lymphoma Unknown status NCT00003337 Phase 3
15 Combination Chemotherapy With or Without Idarubicin and Peripheral Stem Cell Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome Unknown status NCT00002989 Phase 3 busulfan;cyclophosphamide;idarubicin;melphalan
16 Combination Chemotherapy Followed By Radiation Therapy in Treating Patients With Aggressive Non-Hodgkin's Lymphoma Unknown status NCT00053768 Phase 3 EPOCH regimen;cyclophosphamide;doxorubicin hydrochloride;etoposide;prednisone;vincristine sulfate
17 Combination Chemotherapy With or Without Rituximab in Treating Older Patients With Non-Hodgkin's Lymphoma Unknown status NCT00052936 Phase 3 CHOP regimen;cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
18 Interferon Alfa-2b Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Hodgkin's Disease or Non-Hodgkin's Lymphoma Unknown status NCT00003924 Phase 3
19 Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy Not yet recruiting NCT03959085 Phase 3 Cyclophosphamide;Cytarabine;Daunorubicin;Daunorubicin Hydrochloride;Dexamethasone;Doxorubicin;Doxorubicin Hydrochloride;Leucovorin;Leucovorin Calcium;Mercaptopurine;Methotrexate;Pegaspargase;Prednisolone;Thioguanine;Vincristine;Vincristine Sulfate
20 Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia Recruiting NCT02101853 Phase 3 Asparaginase;Cyclophosphamide;Cytarabine;Dexamethasone;Etoposide;Leucovorin Calcium;Mercaptopurine;Methotrexate;Mitoxantrone Hydrochloride;Pegaspargase;Therapeutic Hydrocortisone;Thioguanine;Vincristine Sulfate
21 Blinatumomab in Combination With Chemotherapy in Treating Patients With or Without Down Syndrome and Newly Diagnosed, Standard Risk B-Lymphoblastic Leukemia or Localized B-Lymphoblastic Lymphoma Not yet recruiting NCT03914625 Phase 3 Asparaginase Erwinia chrysanthemi;Cyclophosphamide;Cytarabine;Dexamethasone;Doxorubicin;Doxorubicin Hydrochloride;Leucovorin;Leucovorin Calcium;Mercaptopurine;Mercaptopurine Oral Suspension;Methotrexate;Prednisolone;Prednisone;Thioguanine;Vincristine;Vincristine Sulfate
22 CART-19 Cells For R/R B-ALL Recruiting NCT03391739 Phase 2, Phase 3
23 Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations Suspended NCT02883049 Phase 3 Clofarabine;Cyclophosphamide;Cytarabine;Dasatinib;Daunorubicin Hydrochloride;Dexamethasone;Doxorubicin Hydrochloride;Etoposide;Hydrocortisone Sodium Succinate;Leucovorin Calcium;Mercaptopurine;Methotrexate;Pegaspargase;Prednisone;Thioguanine;Vincristine Sulfate
24 Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia Completed NCT00381680 Phase 3 vincristine sulfate;prednisone;doxorubicin hydrochloride;pegaspargase;cytarabine;methotrexate;dexamethasone;etoposide;cyclophosphamide;leucovorin calcium;asparaginase;mercaptopurine
25 Treatment of Acute Lymphoblastic Leukemia (ALL) in Younger Adults Completed NCT00327678 Phase 3 Rituximab;Imatinib Mesylate
26 Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma Recruiting NCT03117751 Phase 2, Phase 3 Prednisone;Vincristine;Daunorubicin;Pegaspargase;Erwinase®;Rituximab;Cyclophosphamide;Cytarabine;Mercaptopurine;Dasatinib;Methotrexate;Blinatumomab;Ruxolitinib;Bortezomib;Dexamethasone;Doxorubicin;Etoposide;Clofarabine;Vorinostat;Idarubicin;Nelarabine
27 Intravenous Autologous CD19 CAR-T Cells for R/R B-ALL Recruiting NCT03937544 Phase 2, Phase 3 Cyclophosphamide;Fludarabine
28 Effect of Tight Control of Blood Glucose During Hyper-CVAD Chemotherapy For Acute Lymphocytic Leukemia (ALL) Terminated NCT00500240 Phase 3 Insulin Glargine;Insulin Aspart
29 Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma Active, not recruiting NCT01190930 Phase 3 Cyclophosphamide;Cytarabine;Dexamethasone;Doxorubicin Hydrochloride;Leucovorin Calcium;Mercaptopurine;Methotrexate;Pegaspargase;Thioguanine;Vincristine Sulfate
30 Positron Emission Tomography Guided Therapy of Aggressive Non-Hodgkin's Lymphomas Completed NCT00554164 Phase 3 (R-)CHOP protocol;B-ALL protocol;(R-)CHOP protocol;(R-)CHOP protocol
31 S0019 Combination Chemotherapy With or Without Rituximab in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma Terminated NCT00006708 Phase 3 carboplatin;etoposide;ifosfamide
32 Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult T-LBL/ALL Recruiting NCT03564704 Phase 2, Phase 3 Dexamethasone;vincristine;Cyclophosphamide;Idarubicin;Pegaspargase;Adriamycin;Methotrexate;6-mercaptopurine.;Etoposide;Cytarabine;Chidamide
33 Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma Suspended NCT02443077 Phase 3 Carmustine;Cyclophosphamide;Cytarabine;Etoposide;Ibrutinib;Melphalan
34 Budesonide 3x3mg/d Versus Prednisone in Active Autoimmune Hepatitis Completed NCT00838214 Phase 2, Phase 3 budesonide;prednisone
35 Clofarabine or High-Dose Cytarabine and Pegaspargase in Children With ALL Recruiting NCT01228331 Phase 2, Phase 3 Amsacrine;Clofarabine;Cyclophosphamide;Cytarabine;Daunorubicin hydrochloride;Dexamethasone;Doxorubicin hydrochloride;Etoposide phosphate;Mercaptopurine;Methotrexate;Methylprednisolone;Pegaspargase;Thioguanine;Vincristine sulfate
36 International Collaborative Treatment Protocol For Children And Adolescents With Acute Lymphoblastic Leukemia Active, not recruiting NCT01117441 Phase 3 PEG-L-asparaginase;cyclophosphamide;cytarabine;daunorubicin hydrochloride;dexamethasone;doxorubicin hydrochloride;etoposide;ifosfamide;mercaptopurine;methotrexate;prednisone;thioguanine;vincristine sulfate;vindesine;daunoxome;fludarabine
37 Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma or Acute Lymphocytic Leukemia Completed NCT00005977 Phase 3 cyclophosphamide;cytarabine;dexamethasone;doxorubicin hydrochloride;etoposide;ifosfamide;leucovorin calcium;methotrexate;vincristine sulfate
38 Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications Completed NCT00799461 Phase 3
39 Comparison of Two Salvage Chemotherapy Regimens Before Autologous Stem Cell Transplantation With or Without Maintenance Rituximab in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma Completed NCT00078949 Phase 3 cisplatin;cytarabine;dexamethasone;gemcitabine hydrochloride
40 Double Cord Versus Haploidentical (BMT CTN 1101) Active, not recruiting NCT01597778 Phase 3
41 Interleukin-2 or Observation Following Radiation Therapy, Combination Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent Non-Hodgkin's Lymphoma Completed NCT00002649 Phase 3 cyclophosphamide;etoposide
42 Mature B-Cell Lymphoma And Leukemia Study III Recruiting NCT01046825 Phase 2, Phase 3 COPAD;COP, COPD M3, CYM;COP, COPADM8, CYVE
43 Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Previously Untreated HIV-Associated Non-Hodgkin's Lymphoma Completed NCT00003595 Phase 3 CHOP regimen;cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
44 Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial Completed NCT00750009 Phase 3
45 Prevention of Infection in Patients With Hematologic Cancer and Persistent Fever Caused by a Low White Blood Cell Count Completed NCT00003805 Phase 3 piperacillin sodium;piperacillin-tazobactam;tazobactam sodium;vancomycin
46 Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter Completed NCT00006083 Phase 3 Fragmin
47 Radiation Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma Who Have Undergone Stem Cell Transplantation Completed NCT00031668 Phase 3
48 St. John's Wort in Relieving Fatigue in Patients Undergoing Chemotherapy or Hormone Therapy for Cancer Completed NCT00005805 Phase 3
49 American Ginseng in Treating Patients With Fatigue Caused by Cancer Completed NCT00719563 Phase 3 American ginseng
50 Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain Completed NCT00666211 Phase 3

Search NIH Clinical Center for Burkitt Lymphoma

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Burkitt Lymphoma cell therapies at LifeMap Discovery.

Cochrane evidence based reviews: burkitt lymphoma

Genetic Tests for Burkitt Lymphoma

Genetic tests related to Burkitt Lymphoma:

# Genetic test Affiliating Genes
1 Burkitt Lymphoma 30 MYC

Anatomical Context for Burkitt Lymphoma

MalaCards organs/tissues related to Burkitt Lymphoma:

42
B Cells, Bone, T Cells, Breast, Bone Marrow, Lung, Testes
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Burkitt Lymphoma:
# Tissue Anatomical CompartmentCell Relevance
1 Blood Hematopoietic Bone Marrow Hematopoietic Stem Cells Potential therapeutic candidate
2 Blood Peripheral Blood Mature B-Cells Affected by disease

Publications for Burkitt Lymphoma

Articles related to Burkitt Lymphoma:

(show top 50) (show all 3191)
# Title Authors Year
1
Cryptic insertion of MYC exons 2 and 3 into the IGH locus detected by whole genome sequencing in a case of MYC-negative Burkitt lymphoma. ( 31073073 )
2019
2
Risk factors for Burkitt lymphoma in East African children and minors: a case-control study in malaria-endemic regions in Uganda, Tanzania, and Kenya. ( 31054214 )
2019
3
An unusual case of obstructive jaundice: ampullary Burkitt lymphoma. ( 31032110 )
2019
4
Burkitt lymphoma masquerading as Tolosa-Hunt syndrome in an HIV-seropositive patient. ( 31018683 )
2019
5
Fever and Altered Mental Status in an Adolescent Male With Burkitt Lymphoma. ( 31007058 )
2019
6
MDM4 is targeted by 1q gain and drives disease in Burkitt lymphoma. ( 31000522 )
2019
7
Burkitt Lymphoma of the Duodenum: An Uncommon Phenomenon. ( 30984432 )
2019
8
The accuracy of diagnosing Burkitt lymphoma in serous effusion specimen: A cytological-histological correlation with ancillary studies. ( 30983044 )
2019
9
Identification of ADGRE5 as discriminating MYC target between Burkitt lymphoma and diffuse large B-cell lymphoma. ( 30953469 )
2019
10
ERK-dependent IL-6 positive feedback loop mediates resistance against a combined treatment using danusertib and BKM120 in Burkitt lymphoma cell lines. ( 30947576 )
2019
11
Genomic and transcriptomic changes complement each other in the pathogenesis of sporadic Burkitt lymphoma. ( 30926794 )
2019
12
Rhinologic manifestations of Burkitt Lymphoma in a pediatric population: Case series and systematic review. ( 30897372 )
2019
13
Genetic signatures of gene flow and malaria-driven natural selection in sub-Saharan populations of the "endemic Burkitt Lymphoma belt". ( 30849090 )
2019
14
Paediatric burkitt lymphoma presenting as a mandible swelling and intussusception. ( 30846671 )
2019
15
Targeting Burkitt lymphoma with a tumor cell-specific heptamethine carbocyanine-cisplatin conjugate. ( 30840322 )
2019
16
The cost effectiveness of treating Burkitt lymphoma in Uganda. ( 30840316 )
2019
17
Prospective study of Burkitt lymphoma treatment in adolescents and adults in Malawi. ( 30796065 )
2019
18
Prognostic role of ΔMTV and ΔTLG in Burkitt lymphoma. ( 30788775 )
2019
19
Adult Burkitt lymphoma- an Island between lymphomas and leukemias. ( 30788071 )
2019
20
A recurrent clonally distinct burkitt lymphoma case highlights genetic key events contributing to oncogenesis. ( 30779244 )
2019
21
Burkitt-like lymphoma with 11q aberration: A germinal center derived lymphoma genetically unrelated to Burkitt lymphoma. ( 30733272 )
2019
22
Successful treatment of abdominal compartment syndrome with chemotherapy in a patient with a newly diagnosed Burkitt lymphoma. ( 30710879 )
2019
23
Trends in survival of patients with stage I/II Burkitt lymphoma in the United States: A SEER database analysis. ( 30706675 )
2019
24
Sporadic Burkitt Lymphoma with Orbital Extramedullary Infiltration. ( 30675476 )
2019
25
Genome-wide discovery of somatic coding and non-coding mutations in pediatric endemic and sporadic Burkitt lymphoma. ( 30617194 )
2019
26
Ibrutinib significantly inhibited Bruton's tyrosine kinase (BTK) phosphorylation,in-vitro proliferation and enhanced overall survival in a preclinical Burkitt lymphoma (BL) model. ( 30546948 )
2019
27
miR-150 might inhibit cell proliferation and promote cell apoptosis by targeting LMO4 in Burkitt lymphoma. ( 30422313 )
2019
28
Burkitt Lymphoma Presenting With Intracardiac Mass and Tumor Thrombosis in the Anterior Mediastinum With Literature Review. ( 30299348 )
2019
29
Burkitt Lymphoma Presenting as Menorrhagia and a Vaginal Mass in an Adolescent. ( 30278229 )
2019
30
Prognostic role of baseline 18F-FDG PET/CT metabolic parameters in Burkitt lymphoma. ( 30276438 )
2019
31
Fatal Central Nervous System Lymphocytic Vasculitis after Treatment for Burkitt Lymphoma in a Patient with a SH2D1A Mutation. ( 30138256 )
2019
32
Excellent outcomes in children and adolescents with CNS+ Burkitt lymphoma or other mature B-NHL using only intrathecal and systemic chemoimmunotherapy: results from FAB/LMB96 and COG ANHL01P1. ( 30117142 )
2019
33
FAB LMB 96 Regimen for Newly Diagnosed Burkitt Lymphoma in Children: Single-center Experience. ( 30059355 )
2019
34
Sporadic Burkitt Lymphoma Mimicking an Adnexal Tumor. ( 29908337 )
2019
35
Burkitt lymphoma diagnosed on 11C-Methionine cerebral PET in an HIV-positive patient with undetermined brain injury. ( 30061068 )
2019
36
Burkitt's Lymphoma of the Gastrohepatic Omentum: A Malignant Presentation of Pseudoachalasia. ( 30733877 )
2019
37
Traumatic Rupture of Jejunal Burkitt's Lymphoma with Intestinal Transection. ( 30686889 )
2019
38
Burkitt's lymphoma masquerading as a Crohn's flare. ( 30598600 )
2019
39
The interaction between Vav1 and EBNA1 promotes survival of Burkitt's lymphoma cells by down-regulating the expression of Bim. ( 30833082 )
2019
40
IRF4 promotes Epstein-Barr virus activation in Burkitt's lymphoma cells. ( 30907723 )
2019
41
HDAC-selective Inhibitor Cay10603 Has Single Anti-tumour Effect in Burkitt's Lymphoma Cells by Impeding the Cell Cycle. ( 31016515 )
2019
42
Sporadic Burkitt's Lymphoma of the Hypopharynx: A Case Report. ( 31080393 )
2019
43
A Case of Jejunal Intussusception caused by Burkitt Lymphoma in an Acquired Immunodeficiency Syndrome Patient. ( 29637755 )
2018
44
Burkitt's lymphoma presenting as acute appendicitis: a case report. ( 29942479 )
2018
45
Molecular and Cytogenetic Studies in a Child with Burkitt Lymphoma and Ataxia-Telangiectasia Syndrome Harboring MYC Overexpression and Partial Trisomy 8. ( 29071822 )
2018
46
Burkitt lymphoma- a rare but challenging lymphoma. ( 30213397 )
2018
47
Williams-Beuren Syndrome as a Potential Risk Factor for Burkitt Lymphoma. ( 30233648 )
2018
48
Burkitt lymphoma and diffuse large B-cell lymphoma: a unique case of a composite lymphoma of different clonal origin. ( 28583033 )
2018
49
Risk factors for Burkitt lymphoma: a nested case-control study in the UK Clinical Practice Research Datalink. ( 29676453 )
2018
50
Continuous signaling of CD79b and CD19 is required for the fitness of Burkitt lymphoma B cells. ( 29669863 )
2018

Variations for Burkitt Lymphoma

ClinVar genetic disease variations for Burkitt Lymphoma:

6 (show all 12)
# Gene Variation Type Significance SNP ID Assembly Location
1 MYC NM_002467.5(MYC): c.214C> T (p.Pro72Ser) single nucleotide variant Pathogenic rs28933407 GRCh37 Chromosome 8, 128750677: 128750677
2 MYC NM_002467.5(MYC): c.214C> T (p.Pro72Ser) single nucleotide variant Pathogenic rs28933407 GRCh38 Chromosome 8, 127738431: 127738431
3 MYC NM_002467.5(MYC): c.302A> C (p.Asn101Thr) single nucleotide variant Pathogenic/Likely pathogenic rs121918683 GRCh37 Chromosome 8, 128750765: 128750765
4 MYC NM_002467.5(MYC): c.302A> C (p.Asn101Thr) single nucleotide variant Pathogenic/Likely pathogenic rs121918683 GRCh38 Chromosome 8, 127738519: 127738519
5 MYC NM_002467.5(MYC): c.162G> C (p.Glu54Asp) single nucleotide variant Pathogenic rs121918684 GRCh37 Chromosome 8, 128750625: 128750625
6 MYC NM_002467.5(MYC): c.162G> C (p.Glu54Asp) single nucleotide variant Pathogenic rs121918684 GRCh38 Chromosome 8, 127738379: 127738379
7 MYC NM_002467.5(MYC): c.220C> G (p.Pro74Ala) single nucleotide variant Pathogenic rs121918685 GRCh37 Chromosome 8, 128750683: 128750683
8 MYC NM_002467.5(MYC): c.220C> G (p.Pro74Ala) single nucleotide variant Pathogenic rs121918685 GRCh38 Chromosome 8, 127738437: 127738437
9 PMS2 NM_000535.6(PMS2): c.736_741delCCCCCTinsTGTGTGTGAAG (p.Pro246Cysfs) indel Pathogenic rs267608150 GRCh38 Chromosome 7, 5997388: 5997393
10 PMS2 NM_000535.6(PMS2): c.736_741delCCCCCTinsTGTGTGTGAAG (p.Pro246Cysfs) indel Pathogenic rs267608150 GRCh37 Chromosome 7, 6037019: 6037024
11 PMS2 NM_000535.6(PMS2): c.1831dup (p.Ile611Asnfs) duplication Pathogenic rs63750250 GRCh38 Chromosome 7, 5986934: 5986934
12 PMS2 NM_000535.6(PMS2): c.1831dup (p.Ile611Asnfs) duplication Pathogenic rs63750250 GRCh37 Chromosome 7, 6026565: 6026565

Cosmic variations for Burkitt Lymphoma:

9 (show top 50) (show all 76)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM6986772 TRAF2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,B cell lymphoma unspecified c.152A>G p.H51R 9:136898892-136898892 0
2 COSM44103 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Burkitt lymphoma c.737T>A p.M246K 17:7674226-7674226 0
3 COSM43565 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Burkitt lymphoma c.857A>G p.E286G 17:7673763-7673763 0
4 COSM10648 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,B cell lymphoma unspecified c.524G>A p.R175H 17:7675088-7675088 0
5 COSM10777 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Burkitt lymphoma c.715A>G p.N239D 17:7674248-7674248 0
6 COSM45844 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Burkitt lymphoma c.274C>G p.P92A 17:7676095-7676095 0
7 COSM10995 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,B cell lymphoma unspecified c.580C>T p.L194F 17:7674951-7674951 0
8 COSM10725 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Burkitt lymphoma c.701A>G p.Y234C 17:7674262-7674262 0
9 COSM10656 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Burkitt lymphoma c.742C>T p.R248W 17:7674221-7674221 0
10 COSM44910 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,B cell lymphoma unspecified c.403T>A p.C135S 17:7675209-7675209 0
11 COSM43689 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Burkitt lymphoma c.482C>T p.A161V 17:7675130-7675130 0
12 COSM43965 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Burkitt lymphoma c.734G>C p.G245A 17:7674229-7674229 0
13 COSM36146 SOCS1 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Burkitt lymphoma c.391C>A p.Q131K 16:11255088-11255088 0
14 COSM4721653 RICTOR haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,B cell lymphoma unspecified c.3712C>T p.R1238* 5:38950136-38950136 0
15 COSM190567 RHOA haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,B cell lymphoma unspecified c.206T>C p.L69P 3:49368499-49368499 0
16 COSM5274 PTEN haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,B cell lymphoma unspecified c.484G>C p.D162H 10:87933243-87933243 0
17 COSM6987562 PTEN haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,B cell lymphoma unspecified c.331T>G p.W111G 10:87933090-87933090 0
18 COSM5203 PTEN haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Burkitt lymphoma c.496G>C p.V166L 10:87952121-87952121 0
19 COSM5151 PTEN haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Burkitt lymphoma c.1003C>T p.R335* 10:87961095-87961095 0
20 COSM5036 PTEN haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,B cell lymphoma unspecified c.202T>C p.Y68H 10:87925550-87925550 0
21 COSM5227 PTEN haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Burkitt lymphoma c.182A>T p.H61L 10:87925530-87925530 0
22 COSM30627 PIK3CA haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,B cell lymphoma unspecified c.3109G>A p.E1037K 3:179234266-179234266 0
23 COSM5702591 NF2 central nervous system,brain,other,neoplasm c.575A>G p.Y192C 22:29655652-29655652 0
24 COSM85940 MYD88 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,B cell lymphoma unspecified c.794T>C p.L265P 3:38141150-38141150 0
25 COSM6987557 MSH6 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,B cell lymphoma unspecified c.493T>C p.F165L 2:47795929-47795929 0
26 COSM2006760 KMT2D haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,B cell lymphoma unspecified c.12952C>T p.Q4318* 12:49030678-49030678 0
27 COSM6987497 KDM6A haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,B cell lymphoma unspecified c.3406A>G p.M1136V 23:45083581-45083581 0
28 COSM28746 IDH1 central nervous system,brain,other,neoplasm c.395G>A p.R132H 2:208248388-208248388 0
29 COSM28747 IDH1 central nervous system,brain,other,neoplasm c.394C>T p.R132C 2:208248389-208248389 0
30 COSM28748 IDH1 central nervous system,brain,other,neoplasm c.394C>A p.R132S 2:208248389-208248389 0
31 COSM28749 IDH1 central nervous system,brain,other,neoplasm c.394C>G p.R132G 2:208248389-208248389 0
32 COSM28750 IDH1 central nervous system,brain,other,neoplasm c.395G>T p.R132L 2:208248388-208248388 0
33 COSM6949886 HGF haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,B cell lymphoma unspecified c.986G>T p.W329L 7:81729659-81729659 0
34 COSM6948355 GRIN2A haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,B cell lymphoma unspecified c.2453C>T p.A818V 16:9768993-9768993 0
35 COSM5702574 FOXO3 central nervous system,brain,other,neoplasm c.583A>T p.K195* 6:108561791-108561791 0
36 COSM37032 EZH2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Burkitt lymphoma c.1937A>G p.Y646C 7:148811635-148811635 0
37 COSM37029 EZH2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,B cell lymphoma unspecified c.1937A>C p.Y646S 7:148811635-148811635 0
38 COSM37031 EZH2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,B cell lymphoma unspecified c.1936T>A p.Y646N 7:148811636-148811636 0
39 COSM52944 DNMT3A haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,B cell lymphoma unspecified c.2645G>A p.R882H 2:25234373-25234373 0
40 COSM6987563 DIS3 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,B cell lymphoma unspecified c.2597A>C p.K866T 13:72761436-72761436 0
41 COSM6987564 CTCF haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,B cell lymphoma unspecified c.1282C>G p.Q428E 16:67621516-67621516 0
42 COSM12475 CDKN2A haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,B cell lymphoma unspecified c.238C>T p.R80* 9:21971121-21971121 0
43 COSM12513 CDKN2A haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Burkitt lymphoma c.298G>T p.A100S 9:21971061-21971061 0
44 COSM22488 ATM haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,B cell lymphoma unspecified c.8494C>T p.R2832C 11:108345818-108345818 0
45 COSM21828 ATM haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,B cell lymphoma unspecified c.2932T>C p.S978P 11:108271261-108271261 0
46 COSM21829 ATM haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,B cell lymphoma unspecified c.8138G>A p.R2713K 11:108335096-108335096 0
47 COSM21827 ATM haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Burkitt lymphoma c.3161C>G p.P1054R 11:108272729-108272729 0
48 COSM21826 ATM haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Burkitt lymphoma c.2572T>C p.F858L 11:108267276-108267276 0
49 COSM21825 ATM haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Burkitt lymphoma c.1229T>C p.V410A 11:108249096-108249096 0
50 COSM5702592 central nervous system,brain,other,neoplasm c.575A>G p.Y192C 22:29655652-29655652 0

Copy number variations for Burkitt Lymphoma from CNVD:

7 (show top 50) (show all 157)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 13309 1 150547027 150552214 Copy number MCL1 Burkitt''s lymphoma
2 17456 1 142870000 177000000 Gain BCA2 Burkitt''s lymphoma
3 17457 1 142870000 177000000 Gain BCL9 Burkitt''s lymphoma
4 17458 1 142870000 177000000 Gain LHX4 Burkitt''s lymphoma
5 17459 1 142870000 177000000 Gain PIAS3 Burkitt''s lymphoma
6 20085 1 15300000 212100000 Insertion NOTCH2 Burkitt''s lymphoma
7 22188 1 166155454 171863618 Gain FASLG Burkitt''s lymphoma
8 25990 1 195253751 195672280 Gain PTPRC Burkitt''s lymphoma
9 26526 1 200970000 201360000 Gain LRRN5 Burkitt''s lymphoma
10 26527 1 200970000 201360000 Gain MDM4 Burkitt''s lymphoma
11 26528 1 200970000 201360000 Gain PIK3C2B Burkitt''s lymphoma
12 26529 1 200970000 201360000 Gain PLEKHA6 Burkitt''s lymphoma
13 26530 1 200970000 201360000 Gain PPP1R15B Burkitt''s lymphoma
14 29698 1 23457835 23714048 Loss E2F2 Burkitt''s lymphoma
15 30116 1 240240000 241350000 Gain ADSS Burkitt''s lymphoma
16 30117 1 240240000 241350000 Gain AKT3 Burkitt''s lymphoma
17 30118 1 240240000 241350000 Gain C1orf100 Burkitt''s lymphoma
18 30119 1 240240000 241350000 Gain C1orf101 Burkitt''s lymphoma
19 30120 1 240240000 241350000 Gain C1orf121 Burkitt''s lymphoma
20 30121 1 240240000 241350000 Gain FAM36A Burkitt''s lymphoma
21 30122 1 240240000 241350000 Gain HNRPU Burkitt''s lymphoma
22 30123 1 240240000 241350000 Gain LOC440742 Burkitt''s lymphoma
23 30124 1 240240000 241350000 Gain ZNF238 Burkitt''s lymphoma
24 42609 10 36983732 37133784 Loss Burkitt''s lymphoma
25 48364 11 1 32410000 Loss FANCF Burkitt''s lymphoma
26 48365 11 1 32410000 Loss PLEKHA7 Burkitt''s lymphoma
27 49723 11 110620000 110810000 Gain C11orf53 Burkitt''s lymphoma
28 49724 11 110620000 110810000 Gain POU2AF1 Burkitt''s lymphoma
29 50222 11 115828212 118580638 Gain Burkitt''s lymphoma
30 50968 11 120700000 134452384 Deletion Burkitt''s lymphoma
31 51055 11 122263650 134452384 Loss Burkitt''s lymphoma
32 51545 11 127825348 127931093 Gain ETS1 Burkitt''s lymphoma
33 64462 12 128465362 132449811 Gain Burkitt''s lymphoma
34 67044 12 35400000 132349534 Insertion Burkitt''s lymphoma
35 70408 12 61724591 82263925 Gain Burkitt''s lymphoma
36 74099 13 100500000 109100000 Insertion Burkitt''s lymphoma
37 74289 13 103640000 112610000 Loss ANKRD10 Burkitt''s lymphoma
38 74290 13 103640000 112610000 Loss ARHGEF7 Burkitt''s lymphoma
39 74291 13 103640000 112610000 Loss COL4A1 Burkitt''s lymphoma
40 74292 13 103640000 112610000 Loss COL4A2 Burkitt''s lymphoma
41 74293 13 103640000 112610000 Loss EFNB2 Burkitt''s lymphoma
42 74294 13 103640000 112610000 Loss ERCC5 Burkitt''s lymphoma
43 74295 13 103640000 112610000 Loss FGF14 Burkitt''s lymphoma
44 74296 13 103640000 112610000 Loss ING1 Burkitt''s lymphoma
45 74297 13 103640000 112610000 Loss IRS2 Burkitt''s lymphoma
46 74298 13 103640000 112610000 Loss LIG4 Burkitt''s lymphoma
47 74299 13 103640000 112610000 Loss PCCA Burkitt''s lymphoma
48 74300 13 103640000 112610000 Loss RAB20 Burkitt''s lymphoma
49 74301 13 103640000 112610000 Loss SLC10A2 Burkitt''s lymphoma
50 74302 13 103640000 112610000 Loss TNFSF13B Burkitt''s lymphoma

Expression for Burkitt Lymphoma

Search GEO for disease gene expression data for Burkitt Lymphoma.

Pathways for Burkitt Lymphoma

Pathways related to Burkitt Lymphoma according to KEGG:

38
# Name Kegg Source Accession
1 Viral carcinogenesis hsa05203
2 Epstein-Barr virus infection hsa05169

Pathways related to Burkitt Lymphoma according to GeneCards Suite gene sharing: